Takeda Advances Elritercept Study in Myelofibrosis, Keeping Anemia-Focused Pipeline in the Spotlight

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.

Takeda’s phase 2 study, officially titled “A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis,” is testing elritercept in adults with myelofibrosis who also suffer from anemia. The goal is to see how safe and tolerable elritercept is when used alone or with the standard myelofibrosis drug ruxolitinib, and whether it can ease disease symptoms and improve anemia, a key unmet need in this patient group.

The study is evaluating elritercept (also known as KER-050 or TAK-226), a subcutaneous injection designed to improve blood cell production and reduce anemia in myelofibrosis. It is being tested both as a stand-alone treatment and in combination with ruxolitinib, an oral JAK inhibitor that is already widely used to treat myelofibrosis-related symptoms and spleen enlargement.

This is an interventional phase 2 trial with a non-randomized, sequential design, meaning participants are assigned to different treatment arms in set groups rather than by chance. The study is open-label, so both doctors and patients know which treatment is being given. The primary purpose is treatment, focusing on safety, tolerability, and signs of benefit rather than direct comparison between arms.

The trial began after initial submission on 23 August 2021 and is currently recruiting, indicating continued confidence in the program. The primary completion and final completion dates have not been disclosed, but the most recent update on 4 February 2026 signals that the protocol and operational plans are active and evolving. For investors, this fresh update suggests the study is progressing and that key safety and early efficacy readouts are still ahead.

From a market perspective, the ongoing development of elritercept could be strategically important for Takeda (TAK). If the drug shows a clear benefit in treating anemia on top of ruxolitinib, it could position Takeda as a key player in supportive care for myelofibrosis, an area where current options are limited. This could support sentiment around Takeda’s hematology and rare disease pipeline, although near-term revenue impact remains speculative given the early stage. For competitors such as Incyte, which markets ruxolitinib, a successful add-on therapy may actually expand overall treatment use rather than displace existing drugs. Investors should watch for interim data on anemia improvement and safety, as positive trends could drive re-rating of Takeda’s pipeline value and attract more interest from long-term, pipeline-focused holders.

The study remains ongoing and recently updated, with further operational and scientific details available on the ClinicalTrials portal under its registered listing.

To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.